please click on the headlines below to read the complete article
November 2015, Press Release - Myeloma Canada Receives a Moral Commitment from the Minister of Health and Social Services, Gaétan Barrette
November 2015, Myeloma Canada Research Network and Karyopharm Initiate MCRN 002 (STOMP) Clinical Trial of Oral Selinexor in Multiple Myeloma.
November 2015, The Board of Directors of Myeloma Canada is pleased to announce the election of Dr. Donna Reece to the Board of Directors of the International Myeloma Society (IMS).
November 2015, The Board of Directors of Myeloma Canada proudly announces the appointment of Ms. Cindy Manchulenko to the International Myeloma Foundation’s Nurse Leadership Board (NLB).
October 2015, Myeloma Canada Submits Application for Multi-Million Dollar Research Grant
October 2015, The 2015 Multiple Myeloma March was a resounding success!
September 2015, Myeloma Canada's Monthly Newletter
This is a new therapy in Canada undergoing Health Canada review as well as a funding review for the treatment of multiple myeloma patients who have received at least one prior therapy. to participate to carfilzomib (Kyprolis®) contact us at firstname.lastname@example.org
SIGNATURE BLOOD CANCER MARCH GIVES BACK TO THE MULTIPLE MYELOMA COMMUNITY-WINNIPEG , September 9, 2015 - To mark the organization’s 10-year anniversary, Myeloma Canada will host its 5th Annual Multiple Myeloma March on September 13, 2015. Funds raised for this incurable and little-known form of blood cancer will be dedicated to advance myeloma research through innovative clinical trials across the country and to provide educational services to patients.
The Myeloma Canada Research Network (MCRN) Moves Forward with Significant Funding Support from Karyopharm Therapeutics. Myeloma Canada is very pleased to announce the first major contribution by a pharmaceutical or biotechnology company supporting the formalization of the Myeloma Canada Research Network (MCRN). Karyopharm Therapeutics has made a significant donation to further the development of the MCRN in helping achieve its goal of advancing collaborative, pan-Canadian myeloma clinical trial research.
August 2015, Myeloma Canada's Monthly Newsletter
Myeloma Canada is proud to support Don Wright running his 88th marathon since diagnosis from multiple myeloma in 2003. Vital Options International says 74-year old cancer patient to run his 88th marathon with myeloma in Edmonton, August 23rd.
Myeloma Canada is seeking proposals for a bilingual mixed-media communication plan. As part of its current three-year strategic plan, the organization is seeking proposals for a bilingual mixed-media communication plan. In parallel to this invitation, Myeloma Canada is also calling for proposals to create its new website.
Overview of the Myeloma Canada Research Network - The goal of the Myeloma Canada Research Network (MCRN) is to improve patient outcomes by advancing myeloma research across the country. The MCRN is the first and only myeloma research group bringing together Canada’s myeloma research leaders from across Canada. From its beginnings in 2009, it has now grown to a network of over 30 scientists, investigators and clinicians representing 16 myeloma research and treatment centres in nine provinces.
Announcement - Patient Advisory Council - Myeloma Canada is pleased to announce the founding of the Patient Advisory Council (PAC). The Council’s creation was inspired by feedback and comments provided by the patients and caregivers who participated in last year’s pan-Canadian consultation meetings.
Ontario Government Approves Funding for Pomalyst® - Myeloma Canada applauds Ontario’s decision to publicly fund Pomalyst® in combination with Decadron® (dexamethasone). Ontario becomes the first province to reimburse Pomalyst® under the Exceptional Access Program (EAP). Pomalyst® is a treatment option for patients whose disease has progressed despite being treated with traditional therapies.
Criteria updates in the Nova Scotia Formulary regarding Lenalidomide (Revlimid®) - Effective December 29, 2014 - Lenalidomide (Revlimid®) was reviewed by the pCODR Expert Review Committee (pERC) and will be listed with the following new criteria.
ASH 2014: The Latest on Blood Cancers – From Advances to Patient Advantages - On Sunday, December 7, 2014, at 8 p.m., live from San Francisco, where the 56th American Society of Hematology (ASH) Annual Meeting is taking place, leading blood cancer experts, advocacy organizations and patients will put data into perspective, showcasing how scientific advances help patients. A recording of the webcast will be available on December 8th. We will share a link to the webcast shortly.
The news briefing is being hosted by Myeloma Canada, the International Myeloma Foundation, the Lymphoma Research Foundation, the MDS Foundation on behalf of the MDS Alliance and the National Patient Advocate Foundation. Join the conversation around the briefing using the hashtag#BCBrief14
Effective November 18, 2014 - Government is enhancing drug programs by adding 10 new drugs - or new indications for existing drugs - to help Islanders battle disease, says Health and Wellness Minister Doug Currie. Find more information on the Catastrophic Drug Program here.
For those of you who wish to follow the discussion, we will be live tweeting about the Summit and the Awareness Day (@MyelomaCanada). You can also follow the hashtag #makemyelomamatter. Be part of the conversation.
Click here to access the Advocacy Summit Toolkit.
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors: